Δευτέρα 12 Ιουνίου 2017

Role for Afatinib in p16-Negative Head and Neck Cancer?

This video reviews results of LUX-Head& Neck 2, a randomized phase III trial that studied afatinib as adjuvant therapy in patients with unresected squamous cell head and neck cancer. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2sRQlPH
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις